Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05463731 · ClinicalTrials.gov registry record · Phase 3

A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)

A Phase 3 study of Alzheimers Disease, sponsored by Eli Lilly and Company.

Active
Registry status
Phase 3
Development phase
1,667
Enrollment target
20
Study locations

NCT05463731 is a Phase 3 study of Alzheimers Disease that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 1,667 participants, below the 4,050-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (59% lower). The trial reports 20 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05463731, a Phase 3 study of Alzheimers Disease, is active but no longer recruiting, sponsored by Eli Lilly and Company.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
1,667 participants
Enrollment target
20
Study locations

Study Summary

The reason for this study is to collect safety and efficacy information regarding the study drug remternetug in participants with early symptomatic Alzheimer's disease (AD).

Conditions Studied

Alzheimers Disease

Interventions

  • DRUG Placebo
  • DRUG Remternetug (SC)
  • DRUG Remternetug (IV)

Study Locations (20)

California

  • Hope Clinical Research, Inc. - Canoga Park
  • North County Neurology Associates - Carlsbad
  • Wr- Pri, Llc - Encino
  • Neuro-Pain Medical Center - Fresno
  • Irvine Clinical Research - Irvine
  • Kaizen Brain Center - La Jolla
  • Anderson Clinical Research - Redlands

Florida

  • JEM Research Institute - Atlantis
  • VIN-Julie Schwartzbard - Aventura
  • Brain Matters Research - Delray Beach
  • Neuropsychiatric Research Center of Southwest Florida - Fort Myers
  • Finlay Medical Research - Greenacres City
  • Encore Research Group- Jacksonville Center for Clinical Research - Jacksonville
  • ClinCloud - Maitland - Maitland

Colorado

  • Mountain Neurological Research Center - Basalt
  • Alpine Clinical Research Center - Boulder
  • Colorado Springs Neurological Associates - Colorado Springs

Connecticut

  • Institute for Neurodegenerative Disorders - New Haven
  • Ki Health Partners, LLc, dba New England Institute for Clinical Research - Stamford

Arizona

  • MD First Research - Chandler - Chandler

Trial Details

FieldValue
Enrollment Target 1,667 participants
Start Date 2022-08-01
Est. Completion 2026-03
Phase Phase 3

Sponsor

Eli Lilly and Company

1,341 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05463731

The ClinicalTrials.gov registry entry for NCT05463731 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 1,667 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,050-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (59% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Alzheimers Disease appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT05463731 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Florida, Colorado.

Frequently Asked Questions

What is clinical trial NCT05463731 about?

NCT05463731 is a clinical study titled "A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)". The reason for this study is to collect safety and efficacy information regarding the study drug remternetug in participants with early symptomatic Alzheimer's disease (AD).

What is the current status of trial NCT05463731?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,667 participants. The study started on 2022-08-01. Estimated completion is 2026-03.

What conditions does trial NCT05463731 study?

This clinical trial studies the following conditions: Alzheimers Disease.

What interventions are being tested in trial NCT05463731?

The interventions under investigation include: Placebo (DRUG), Remternetug (SC) (DRUG), Remternetug (IV) (DRUG).

Who is sponsoring clinical trial NCT05463731?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05463731 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Alzheimers Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Alzheimers Disease

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.